Moderna (XSWX:MRNA) 1-Year Sharpe Ratio: N/A (As of Aug. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:MRNA Moderna Inc XSWX:MRNA
40 GF Score
Price CHF127.46
GF Value CHF23.19
! 7 Warning Signs
View Full Analysis

What is Moderna 1-Year Sharpe Ratio?

The 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past year. As of today (2026-08-21), Moderna's 1-Year Sharpe Ratio is Not available.

Moderna  (XSWX:MRNA) 1-Year Sharpe Ratio Explanation

The 1-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past year. It is calculated as the annualized result of the average monthly excess return divided by its standard deviation over the past year. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.

Moderna 1-Year Sharpe Ratio Related Terms

XSWX:MRNA vs BNTX, INSM, INCY: 1-Year Sharpe Ratio Comparison

For the Biotechnology subindustry, Moderna's 1-Year Sharpe Ratio, along with its competitors' market caps and 1-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Moderna 1-Year Sharpe Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Moderna's 1-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where Moderna's 1-Year Sharpe Ratio falls into.


XSWX:MRNA
40GF Score
Moderna Inc XSWX:MRNA
1-Year Sharpe Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Moderna 1-Year Sharpe Ratio Calculation

The 1-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset. A stock / portfolio's 1-Year Sharpe Ratio can be calculated by dividing the difference between the one-year returns of the investment and the risk-free rate, by the standard deviation of the investment returns over one year.

Is Moderna (XSWX:MRNA) Overvalued in 2026?

Based on GuruFocus' analysis, Moderna stock appears to be overvalued. The current stock price of CHF127.46 is trading 449.6% above its estimated GF Value™ of CHF23.19.

Key valuation signals for XSWX:MRNA:

  • 1-Year Sharpe Ratio: N/A
  • GF Value™: CHF23.19 vs. price of CHF127.46 (449.6% above fair value)
  • GF Score™: 40/100 with 7 warning signs

No single metric tells the full story. See the XSWX:MRNA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Moderna Business Description

Address 325 Binney Street, Cambridge, MA, USA, 02142
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
40GF Score

Get the complete analysis for XSWX:MRNA

1-Year Sharpe Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF127.46
Price
CHF23.19
GF Value